hVIVO has announced that its German subsidiary CRS has signed contracts worth over £5m since September, strengthening the group’s sales pipeline and orderbook for 2026 and beyond. These trials are due to commence this year and in 1H26 with the majority of revenue to be recognised in FY26. The studies will take place at CRS’s Mannheim and Kiel sites, targeting multiple therapeutic areas including cardiometabolic, dermatology, infectious disease, renal impairment, and cancer with recruitment suppo ....
